Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Cancer patient outcomes correlate with activating-KIR/ligand repertoires associated with distinct NK cell transcriptomic profiles.

BACKGROUND Rates of cancer cure increase; however, recurrence and refractoriness remain clinical challenges that require alternative therapeutic strategies. Natural killer (NK) cells could play a decisive role if their antitumor reactivity can be enhanced. The interaction between killer-cell immunoglobulin-like recepto...

I. Ruiz-Lorente, Andrés Vallejo-Pulido, A. López-Abad et al. · 0 citations
Open access Sep 2026

Selinexor potentiates NK cell activation against multiple myeloma

Abstract Selinexor is a first-in-class selective inhibitor of nuclear export targeting exportin-1 (XPO1) and approved for the treatment of multiple myeloma (MM). Selinexor has previously been shown to enhance natural killer (NK) cell activation against lymphoma cells via disruption of the NKG2A:HLA-E immune checkpoint...

Daniel T. Harding, Lara V. Graham, Laura G. Bartlett et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.